JP2020504733A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504733A5
JP2020504733A5 JP2019533490A JP2019533490A JP2020504733A5 JP 2020504733 A5 JP2020504733 A5 JP 2020504733A5 JP 2019533490 A JP2019533490 A JP 2019533490A JP 2019533490 A JP2019533490 A JP 2019533490A JP 2020504733 A5 JP2020504733 A5 JP 2020504733A5
Authority
JP
Japan
Prior art keywords
amino
methyl
oxy
propan
phosphoryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533490A
Other languages
English (en)
Japanese (ja)
Other versions
JP6938637B2 (ja
JP2020504733A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/067470 external-priority patent/WO2018119013A1/en
Publication of JP2020504733A publication Critical patent/JP2020504733A/ja
Publication of JP2020504733A5 publication Critical patent/JP2020504733A5/ja
Application granted granted Critical
Publication of JP6938637B2 publication Critical patent/JP6938637B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533490A 2016-12-22 2017-12-20 テノホビルの抗ウイルス性脂肪族エステルプロドラッグ Expired - Fee Related JP6938637B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662437753P 2016-12-22 2016-12-22
US62/437,753 2016-12-22
US201762574493P 2017-10-19 2017-10-19
US62/574,493 2017-10-19
PCT/US2017/067470 WO2018119013A1 (en) 2016-12-22 2017-12-20 Antiviral aliphatic ester prodrugs of tenofovir

Publications (3)

Publication Number Publication Date
JP2020504733A JP2020504733A (ja) 2020-02-13
JP2020504733A5 true JP2020504733A5 (enExample) 2021-01-28
JP6938637B2 JP6938637B2 (ja) 2021-09-22

Family

ID=60972454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533490A Expired - Fee Related JP6938637B2 (ja) 2016-12-22 2017-12-20 テノホビルの抗ウイルス性脂肪族エステルプロドラッグ

Country Status (13)

Country Link
US (1) US10519159B2 (enExample)
EP (1) EP3559011B1 (enExample)
JP (1) JP6938637B2 (enExample)
KR (1) KR20190100250A (enExample)
CN (1) CN110099912B (enExample)
AU (1) AU2017379850B2 (enExample)
BR (1) BR112019013017A2 (enExample)
CA (1) CA3047573A1 (enExample)
MA (1) MA47094A (enExample)
MX (1) MX388757B (enExample)
RU (1) RU2759902C2 (enExample)
TW (1) TW201829412A (enExample)
WO (1) WO2018119013A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100108A1 (en) 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2018039157A1 (en) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
EP3558322B1 (en) 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
EP3730503B8 (en) * 2017-12-21 2026-03-18 Shenzhen TargetRx Co., Ltd. Antiviral nucleoside reverse transcriptase inhibitor
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
CN108586239B (zh) * 2018-04-11 2020-12-29 深圳市前海博扬研究院有限公司 一种3-羟基丙酸甲酯的制备方法
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
EP3823629B1 (en) 2018-07-19 2024-12-25 Merck Sharp & Dohme LLC Phosphinic amide prodrugs of tenofovir
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CN111018916B (zh) * 2019-12-30 2022-04-29 天津天士力圣特制药有限公司 一种替诺福韦苯基烷基酯膦酰胺前体的合成方法
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
LT4192474T (lt) 2020-08-07 2025-11-25 Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas
IL301560A (en) * 2020-09-23 2023-05-01 Primefour Therapeutics Inc Method for treating cancer with a reverse transcriptase inhibitor
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
TW202608468A (zh) 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
US7553825B2 (en) 2003-12-30 2009-06-30 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
EP1879657A2 (en) 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN102887901B (zh) 2011-07-01 2015-01-07 四川好医生攀西药业有限责任公司 无环核苷酸类似物及其制备方法和应用
AP3639A (en) 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
CN107312039B (zh) * 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN103435672A (zh) * 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
WO2015197006A1 (zh) * 2014-06-25 2015-12-30 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
CN106188139B (zh) * 2015-05-29 2020-02-18 江苏天士力帝益药业有限公司 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
WO2017027434A1 (en) 2015-08-10 2017-02-16 Merck Sharp & Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
CN106167504A (zh) 2015-11-04 2016-11-30 洛阳聚慧医药科技有限公司 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用
WO2017100108A1 (en) 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
RU2604068C1 (ru) * 2015-12-10 2016-12-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук N-(2-аминопурин-6-ил)глицил-(s)-глутаминовая кислота, обладающая противотуберкулёзной активностью
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2018039157A1 (en) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
EP3558322B1 (en) 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds

Similar Documents

Publication Publication Date Title
RU2019122414A (ru) Антивирусные алифатические сложноэфирные пролекарства тенофовира
JP2017105793A5 (enExample)
JP2016179996A5 (enExample)
JP2021063088A5 (enExample)
RU2019122625A (ru) Противовирусные бензиламин-фосфодиамидные соединения
JP2019500387A5 (enExample)
JP2017533968A5 (enExample)
JP2014508804A5 (enExample)
JP2018035142A5 (enExample)
JP2017518334A5 (enExample)
JP2017523225A5 (enExample)
JP2013518107A5 (enExample)
JP2010501584A5 (enExample)
MA46038A (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
JP2019501130A5 (enExample)
JP2017526677A5 (enExample)
JP2014505107A5 (enExample)
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
JP2020512337A5 (enExample)
JP2017517565A5 (enExample)
JP2020128426A5 (enExample)
TN2013000257A1 (en) Immunosuppressant formulations
RU2016142611A (ru) Пролекарственные средства ингибиторов обратной транскриптазы вич
JP2019531356A5 (enExample)
RU2007106930A (ru) Производные хиназолина